An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
Recruiting · NCT06487624 · Registry updated 2026-04-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors | Bone Diseases, Developmental, Camurati-Engelmann disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, bone disorder, hereditary disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, musculoskeletal system disorder, neoplasm, osteochondrodysplasia | Recruiting | Phase 1 | 2026-04-13 | NCT06487624 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| FBD Biologics Limited | 7 |
| HanchorBio Inc. | 2 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung City | Taiwan | 48 |
| Prisma Health-Upstate | Greenville | United States | 7 |
| Southern Medical University Zhujiang Hospital | Zhujiang | China | 1 |
| The first affiliated hospital, Zhejiang university school of medicine | Hangzhou | China | 27 |
| Xuzhou Central Hospital | Xuzhou | China | 16 |
| Yantai YuHuangDing Hospital | Yantai | China | 20 |
| Zhejiang Provincial Cancer Hospital | Hangzhou | China | 2 |